With price tags that can hit a mind-boggling $100,000 for an annual supply, critics are increasingly questioning whether certain cancer drugs are worth the price, particularly given that they may only extent a patient's life for a few months. policymakers and clinicians are asking whether society should invest such a large sum on patients who are about to die either way. Article [1]